Novartis India Stake Sale: Shares Surge 17% on ChrysCapital Deal

Introduction

Shares of Novartis India Ltd. surged over 17% on Friday following the announcement that its Swiss parent company, Novartis AG, has agreed to sell its entire 70.68% controlling stake. The buyer is a consortium of investors led by private equity firm ChrysCapital. This landmark transaction triggers a mandatory open offer for public shareholders and marks a significant shift in ownership for the Indian pharmaceutical company.

The Acquisition Agreement

On February 19, 2026, Novartis AG entered into a definitive share purchase agreement to divest its holdings in Novartis India Limited. The deal involves the sale of 1,74,50,680 equity shares to a consortium comprising WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners. The total consideration for this controlling stake amounts to approximately ₹1,445.89 crore. This move follows a strategic review initiated by Novartis AG in February 2024 aimed at optimizing its global operations.

A Differentiated Pricing Structure

The transaction is notable for its differentiated pricing. While the acquirers are acting as a consortium, the price per share varies among them. WaveRise Investments will acquire the largest portion of the stake at a higher price, which also sets the price for the subsequent open offer.

Mandatory Open Offer for Public Shareholders

As per the regulations of the Securities and Exchange Board of India (SEBI), the acquisition of a controlling stake triggers a mandatory open offer to the public shareholders. The consortium has announced an offer to acquire an additional 26% of Novartis India's voting share capital. This translates to 64,19,608 equity shares at a price of ₹860.64 per share. The total potential outlay for the open offer is valued at up to ₹552.49 crore. Axis Capital Limited has been appointed to manage the open offer process.

Market Reacts Positively

The market responded with strong optimism to the news. Novartis India's stock price jumped by more than 17% in early trading on Friday, reaching ₹974 per share. This was a significant increase from the previous day's closing price of ₹830.45. The open offer price of ₹860.64 represents a 3.64% premium over Thursday's close. The rally pushed the company's market capitalization to approximately ₹2,375 crore.

Post-Transaction Changes and Covenants

Upon completion of the transaction, the ChrysCapital-led consortium will assume control and be classified as the new promoters of Novartis India. Consequently, Novartis AG will cease to be the promoter and will be reclassified into the public shareholder category. As part of the agreement, Novartis India has committed to changing its name within 120 days of the deal's closing to remove any reference to the Novartis brand, subject to regulatory approvals. The company has also provided customary warranties to the acquirers on a non-recourse basis.

Future Ownership Scenarios

The final ownership structure will depend on the response to the mandatory open offer. The two primary scenarios are as follows:

Novartis AG's Strategic Rationale

For Novartis AG, this divestment is a key step in its global strategy to transform into a pure-play innovative medicines company. By selling its stake in the listed Indian entity, the parent company can focus its resources on its core research and development pipeline and its global commercial operations. This aligns with a broader industry trend of large pharmaceutical companies streamlining their portfolios.

Continued Novartis Presence in India

It is important to note that Novartis is not exiting India. The sale is limited to the publicly listed entity, Novartis India Limited. Novartis will continue to operate in the country through Novartis Healthcare Private Limited (NHPL), its wholly-owned subsidiary. NHPL houses the commercial arm, a corporate center in Hyderabad, and R&D teams conducting clinical trials across more than 300 sites. The company remains committed to expanding its portfolio in India, particularly in the Cardio Renal Metabolic and Oncology segments.

Conclusion

The sale of Novartis AG's stake in its Indian-listed entity to the ChrysCapital consortium represents a major shift in the Indian pharmaceutical landscape. The transaction has been well-received by the market, reflecting confidence in the new ownership. With the deal expected to close in the third quarter of 2026, all eyes will be on the upcoming open offer and the strategic direction the new promoters will chart for the company.